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ORIGINAL ARTICLE – MELANOMA
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ABSTRACT
Background. This study compares well-being, recur-
rences, and deaths of early-stage cutaneous melanoma
patients in follow-up, as recommended in the Dutch
guideline, with that of patients in a stage-adjusted reduced
follow-up schedule, 3 years after diagnosis, as well as
costs.
Methods. Overall, 180 eligible pathological American
Joint Committee on Cancer (AJCC) stage IB–IIC, sentinel
node staged, melanoma patients (response rate = 87%,
48% male, median age 57 years), randomized into a con-
ventional (CSG, n = 93) or experimental (ESG, n = 87)
follow-up schedule group, completed patient-reported
outcome measures (PROMs) at diagnosis (T1): State-Trait
Anxiety Inventory–State version (STAI-S), Cancer Worry
Scale (CWS), Impact of Event Scale (IES), and RAND-36
(Mental and Physical Component scales [PCS/MCS]).
Three years later (T3), 110 patients (CSG, n = 56; ESG,
n = 54) completed PROMs, while 42 declined (23%).
Results. Repeated measures analyses of variance (ANO-
VAs) showed a significant group effect on the IES
(p = 0.001) in favor of the ESG, and on the RAND-36 PCS
(p = 0.02) favoring the CSG. Mean IES and CWS scores
decreased significantly over time, while those on the
RAND-36 MCS and PCS increased. Effect sizes were
small. Twenty-five patients developed a recurrence or
second primary melanoma, of whom 13 patients died
within 3 years. Cox proportional hazards models showed
no differences between groups in recurrence-free survival
(hazard ratio [HR] 0.71 [0.32–1.58]; p = 0.400) and dis-
ease-free survival (HR 1.24 [0.42–3.71]; p = 0.690). Costs
per patient after 3 years (computed for 77.3% of patients)
were 39% lower in the ESG.
Conclusion. These results seemingly support the notion
that a stage-adjusted reduced follow-up schedule forms an
appropriate, safe, and cost-effective alternative for patho-
logical AJCC stage IB–IIC melanoma patients to the
follow-up regimen as advised in the current melanoma
guideline.
The worldwide incidence of cutaneous melanoma has
increased over the past decade.1 In The Netherlands, the
incidence of melanoma quadrupled between 1990 and
2018, from 1561 to 7046 new cases.2 However, the
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increase in mortality was lower. This rate doubled between
1990 and 2010, from 348 to 783 cases, but then stabilized.
In 2017, 796 patients died of melanoma.3 Consequently,
the prevalence of melanoma is increasing in The
Netherlands.
Increasing prevalence results in a growing number of
patients in follow-up. Most guidelines regarding follow-up
schedules recommend at least 5-year, 10-year, or lifelong
surveillance, which makes melanoma follow-up a burden
in both time and financial costs.4,5 Additionally, patients
are exposed to many outpatient clinic or general practi-
tioner (GP) visits, which may result in emotional stress.5–7
Most of the recommendations in the current guidelines
are based on recurrence risk, early detection, and, conse-
quently, improved survival.8–12 Almost 90% of the
recurrences occur in the first 3 years after primary diag-
nosis.4,9,12–14 Patients with a higher stage at primary
diagnosis have a higher risk of recurrence, and the risk of
recurrence after 10 years follow-up is low (2.4%).6,7,10,15
The lack of consensus in guidelines regarding the fol-
low-up of cutaneous melanoma patients was the reason to
initiate the melanoma follow-up study (MELFO). Prelim-
inary 1-year results showed that a stage-adjusted, reduced
follow-up schedule adversely affected neither patients’
well-being nor the number of recurrences or melanoma
deaths, and that financial costs were lower compared with
the conventional follow-up schedule recommended in the
Dutch guideline.16
The aims of the present study were to examine com-
parability in (1) well-being and (2) the number and time of
recurrences and deaths of early-staged melanoma patients
who were subjected to the follow-up schedule advised in
the Dutch guideline, as well as patients who received a
stage-adjusted reduced follow-up schedule, 3 years after
diagnosis. The hypotheses were that there would be no
differences between the two groups in these outcomes and




Detailed methods of this multicenter, randomized clin-
ical trial (NCT0108004), initiated by the Department of
Surgical Oncology of the University Medical Center
Groningen (UMCG), have been described previously.16
Participants were randomized into two groups: one group
following the conventional schedule recommended in the
Dutch Melanoma guideline, and one group whose follow-
up was a stage-adjusted reduced schedule (Table 1). The
primary endpoint was patients’ well-being. Secondary
endpoints were recurrences, melanoma-related deaths, and
costs.16
Patients and Procedure
Inclusion criteria were sentinel lymph node-negative
melanoma patients with pathological American Joint on
Cancer Committee (AJCC, 7th edition) stage IB–IIC, who
had undergone surgery with a curative intent between 2006
and 2013. Patients aged \ 18 or [ 85 years, those not
mastering the Dutch language sufficiently, and those who
had another malignancy were excluded.
Eligible patients were randomized into the conventional
(CSG) or experimental schedule group (ESG) after giving
informed consent. The Netherlands Comprehensive Cancer
Organization (IKNL) performed randomization and data
management.
Patients completed questionnaires at study entry, which
was shortly after diagnosis (T1), and at 1 (T2) and 3 years
later (T3). Patients were excluded from T2 or T3 in cases
of recurrence, a second primary, or when they had died.
Clinicians provided follow-up information on all patients
included at T1 during the 3 years of the study16 or until
patients developed a recurrence, a second primary, or died.
The present study focused on T1 and T3.
This study was approved by the Medical Ethics Com-
mittee of the UMCG (METc2004.127).
Instruments
Patients answered questions on sex, age, level of edu-
cation, relationship status, daily activities, and
comorbidities at T1. They also answered questions on
schedule satisfaction, frequency of self-inspection, and the
number of melanoma-related GP visits at T1 and T3.
Medical specialists provided diagnostic (primary mela-
noma site, Breslow thickness, ulceration, AJCC
classification) and follow-up information (date of every
outpatient visit, date and location of recurrence, date and
cause of death).
Patients completed the following patient-reported out-
come measures (PROMs) at T1 and T3:
1. The State-Trait Anxiety Inventory–State version
(STAI-S), a 20-item questionnaire measuring the
transitory emotional condition of stress or tension
perceived by the patient. Items could be scored on a
4-point scale ranging from ‘not at all’ (1) to ‘very
much’ (4) [range 20–80].17
2. The three-item Cancer Worry Scale (CWS) measuring
concerns about developing cancer again and the impact
on daily activities.18–20 Higher scores mean more
worries (range 3–12).
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3. The 15-item Impact of Event Scale (IES) evaluating
the extent to which patients suffer from life hazards, in
this case having a melanoma, in terms of avoidance
and intrusion.21,22 A higher score (range 0–75) corre-
sponds to a higher level of stress response symptoms
(SRS).
4. The RAND-36, a 36-item health-related quality-of-life
questionnaire, of which the mental component (MCS)
and physical component (PCS) summary scores were
used. The summary scores are standardized, with a
mean of 50 and a standard deviation of 10.23
Total melanoma-related hospital costs were calculated
for 51 patients from a University Medical Center
(Groningen) and 34 patients from a large teaching hospital
(Isala Clinics, Zwolle) participating at T3 (representing
77.3% of participants). Costs per melanoma patient are
considered largely comparable between hospitals as a
consequence of the financing system in The Netherlands,
which is a price-competitive reimbursement system. Costs
per patient are calculated using diagnosis-treatment com-
binations (DBCs). DBCs are developed for a combination
of interventions and treatments that belong to a certain
diagnosis.24 These DBCs are fixed prices and are based on
agreement between hospitals and health insurance compa-
nies. Costs taken into account included all follow-up visits
and telephone consultations, as well as detection and
treatment of recurrences. Expenses for GP consultations
were not taken into account.
Statistical Analysis
The power analysis performed has been described pre-
viously.16 Statistical analyses were performed using IBM
SPSS statistics version 22 (IBM Corporation, Armonk, NY,
USA). Patient characteristics were described, and com-
parisons between study groups were performed using
independent t tests, Mann–Whitney U tests, Chi square
tests, or Fisher’s exact tests, as appropriate. Repeated
measures analyses of variance (ANOVAs) were conducted
to examine differences between groups, time differences,
and interaction effects in PROMs. Effect sizes (ESs) were
computed to examine clinical relevance when a difference
was found to be statistically significant. ES values C 0.5
were considered large, those between 0.3 and 0.5 were
considered moderate, and those \ 0.3 were considered
small.25 Cox proportional hazards models were computed
to examine the effect of the group on recurrence-free sur-
vival (RFS) and disease-free survival (DFS).
p values\ 0.05 were considered statistically significant.
RESULTS
Of the 207 patients who were eligible for inclusion, 27
refused participation (response rate = 87%),16 resulting in
180 participants being included at T1, of whom 87 were
male (48%) and median age was 57 years (range 20–85).
Patients were randomized into a conventional (CSG,
n = 93) or experimental (ESG, n = 87) follow-up schedule
group. No significant differences between study groups
were found in sociodemographic or illness-related charac-
teristics at T1.16
At T3, 110 patients completed the questionnaire. Of the
70 patients who did not, 28 were excluded (recurrent dis-
ease, a second primary, or death) and 42 (23%) declined to
complete T3 questionnaires (Fig. 1). No significant dif-
ferences were found in sociodemographic and illness-
related variables between T3 CSG and ESG participants
(Table 2). T3 participants and those who dropped out were
comparable in T1 sociodemographic and illness-related
variables, as well as in mean PROMs scores (data not
shown).
No significant between-group differences in satisfaction
with the follow-up schedule (p = 0.162) were found at T3,
or in reason for dissatisfaction (p = 0.444). Adherence with
the assigned follow-up schedule differed significantly
between groups (p = 0.031). Significantly more ESG than
CSG patients paid more visits to the medical specialist than
scheduled. Of the patients who paid extra visits, 16 (64%)
paid only one extra visit during the 3-year period. Medians
for the number of fewer or extra visits did not differ
TABLE 1 Frequency of
follow-up visits for the
conventional follow-up
schedule, as recommended by
the Dutch Melanoma guideline,
and a reduced and stage-
adjusted experimental follow-up
schedule16
Conventional follow-up schedule Experimental follow-up schedule
Yearsa 1 2 3 4 5 6–10 Yearsa 1 2 3 4 5 6–10
AJCC stage AJCC stage
IB 4 3 2 2 2 IB 1 1 1 1 1 1
IIA 4 3 2 2 2 1 IIA 2 2 1 1 1 1
IIB 4 3 2 2 2 1 IIB 3 3 2 1 1 1
IIC 4 3 2 2 2 1 IIC 3 3 2 1 1 1
AJCC American Joint Committee on Cancer, 7th edition
aYear after surgery for primary melanoma
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between groups (p = 0.466 and p = 0.547, respectively)
[Table 2]. Adherence to the assigned follow-up schedule
and schedule satisfaction were not significantly related
(Fisher’s exact test, p = 0.154). No significant difference
was found between study groups in terms of melanoma-
related GP visits (p = 0.439) or when combining extra
visits to the medical specialist with the melanoma-related
GP visits (p = 0.221). Of the 83 patients who paid extra GP
visits, 46% did this only once (Table 2).
All patients reported performing self-inspection, except
one CSG and one ESG patient. The frequency of self-in-
spection did not differ significantly between groups
(p = 0.548) (Table 2).
Patient-Reported Outcome Measures
Repeated measures ANOVA showed a significant
between-group effect on the IES (p = 0.001) and the
RAND-36 PCS (p = 0.02). ESG patients had significantly
lower IES mean scores at T1 and T3, and had a signifi-
cantly lower RAND-36 PCS score at T1 (t test; p = 0.006)
but not at T3 (t test; p = 0.264). ESs were small. Over time,
a significant decrease was found in mean scores on the
CWS and IES, and an increase on the RAND-36 MCS and
PCS scores (all p\ 0.001). ESs were small. No significant
interaction effects were found (Table 3).
Melanoma Recurrences and Deaths During the 3-Year
Follow-Up
At T3, 25 patients (13.9%) had been diagnosed with
recurrent disease or a second primary—15 CSG patients
(16.1%) and 10 ESG patients (12%) [p = 0.397]. The Cox
proportional hazards model showed no significant differ-
ence between groups in RFS (hazard ratio [HR] 0.71
[0.32–1.58]; p = 0.400). Of the recurrences or second pri-
maries, 15 were diagnosed within the first year16 and 10
(40%) were diagnosed between T1 and T3. No significant
differences were found between groups in terms of
locoregional and/or distant disease or second primaries
(p = 0.457) at T3. Sixteen recurrences (66.7%) were
detected by the patients themselves, and eight (33.3%)
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FIG. 1 Flowchart of inclusion and randomization
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TABLE 2 Descriptives of sociodemographic and illness-related characteristics at T1, and follow-up-related questions at T3 of the 110




schedule [n = 56]
Experimental




Female 56 (50.9) 25 (44.6) 31 (57.4)
Male 54 (49.1) 31 (55.4) 23 (42.6)
Age, years 0.161d
Mean ± SD (range) 56 ± 13 (24–81) 55 ± 14 (26–81) 58 ± 11 (24–78)
Level of educationa 0.312c
High 44 (40) 24 (42.9) 20 (37.0)
Intermediate 44 (40) 24 (42.9) 20 (37.0)
Low 22 (20) 8 (14.2) 14 (26.0)
Relationship 0.189c
With partner 95 (86.4) 46 (82.1) 49 (90.7)
Without partner 15 (13.6) 10 (17.9) 5 (9.3)
Daily activities 0.257c
Employed for wages 59 (53.6) 33 (58.9) 26 (48.1)
Not employed for wages 51 (46.4) 23 (41.1) 28 (51.9)
Presence of comorbidities 0.053c
No 71 (64.5) 41 (73.2) 30 (55.6)
Yes 39 (35.5) 15 (26.8) 24 (44.4)
Primary melanoma site 0.463c
Lower extremity 32 (29.1) 20 (35.7) 12 (22.2)
Upper extremity 21 (19.1) 9 (16.1) 12 (22.2)
Trunk 46 (41.8) 22 (39.3) 24 (44.4)
Head/neck 11 (10) 5 (8.9) 6 (11.2)
Breslow thickness, mm 0.123c
\ 1.0 8 (7.3) 1 (1.8) 7 (13.0)
1.00–1.99 63 (57.3) 36 (64.3) 27 (50)
2.00–3.99 31 (28.2) 15 (26.8) 16 (29.6)
C 4.00 8 (7.3) 4 (7.1) 4 (7.4)
Median (range) 1.7 (0.6–8.0) 1.6 (0.9–8.0) 1.7 (0.6–7.3)
Ulceration 0.215c
No 85 (77.3) 46 (82.1) 39 (72.2)
Yes 25 (22.7) 10 (17.9) 15 (27.8)
AJCC classification 0.487c
Ib 65 (59.1) 34 (60.7) 31 (57.4)
IIa 24 (21.8) 14 (25.0) 10 (18.5)
IIb 15 (13.6) 5 (8.9) 10 (18.5)
IIc 6 (5.5) 3 (5.4) 3 (5.6)
Follow-up-related questions at T3
Schedule satisfactionb 0.162c
No 9 (8.5) 7 (13) 2 (3.9)
Yes 96 (91.5) 47 (87) 49 (96.1)
Missing 5 2 3





schedule [n = 56]
Experimental
schedule [n = 54]
p value
Reason for dissatisfactionb 0.444e
Wish for less visits 4 (44.4) 4 (57.1)
Wish for more visits 5 (55.6) 3 (42.9) 2 (100)
Adherence to follow-up schedule 0.031c
Less outpatient clinic visits than scheduled 11 (10) 7 (12.5) 4 (7.4)
1 visit less 6 (54.5) 3 (42.8) 3 (75)
2 visits less 3 (27.3) 3 (42.8)
3–4 visits less 2 (18.2) 1 (14.3) 1 (25)
Median (range) 1 (1–4) 2 (1–4) 1 (1–3) 0.466f
Conform schedule 74 (67) 42 (75) 32 (59.3)
More outpatient clinic visits than scheduled 25 (23) 7 (12.5) 18 (33.3)
?1 extra visit 16 (64) 4 (57.1) 12 (66.7)
?2 extra visits 5 (20) 1 (14.3) 4 (22.2)
?3–5 extra visits 4 (16) 2 (28.6) 2 (11.1)
Median (range) 1 (1–5) 1 (1–4) 1 (1–5) 0.547f
Melanoma-related GP visits 0.439c
No 27 (24.5) 12 (21.4) 15 (27.8)
Yes 83 (75.5) 44 (78.6) 39 (72.2)
Extra GP visits
?1 visit 38 (45.8) 21 (47.7) 17 (43.6)
?2 visits 29 (34.9) 17 (38.6) 12 (30.8)
?3–5 visits 16 (19.3) 6 (13.6) 10 (25.7)
Median (range) 2 (1–5) 2 (1–5) 2 (1–5) 0.425f
Total (hospital ? GP) extra visits 87 (79.1) 44 (78.6) 43 (79.6) 0.221e
?1 extra visit 33 (37.9) 18 (40.9) 15 (34.9)
?2 extra visits 25 (28.7) 16 (36.4) 9 (34.9)
?3 extra visits 13 (14.9) 4 (9.1) 9 (20.9)
?4 extra visits 10 (11.5) 3 (6.8) 7 (16.3)
?5–7 extra visits 6 (6.9) 3 (6.8) 3 (7.0)
Frequency of self-inspectionb 0.548c
Every week 18 (16.4) 8 (14.3) 10 (18.5)
Every month 52 (47.3) 31 (55.4) 21 (38.9)
Once every 3 months 26 (23.6) 11 (19.6) 15 (27.8)
Less than every 3 months 12 (10.9) 5 (8.9) 7 (13.0)
Never 2 (1.8) 1 (1.8) 1 (1.9)
Hospital costs (3 years) [€] n = 43 n = 42
Follow-up visits 56,387.89 32,374.07
Specialist 51,431.10 29,655.13
NP 2538.10 1177.70
Telephone consultation 2418.89 1541.24
Diagnostics 12,344.22 6931.95
Laboratory testing 322.76 6.00
Ultrasonography 2044.96 819.96
CT scan 775.89 872.00
FDG-PET-CT scan 2771.42 1588.00
Pathology/cytology 6429.19 3645.99
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not differ when considering who detected a recurrence
(p = 0.204) (Table 4).
Of the 25 patients who developed a recurrence or second
primary during the 3-year period, 13 (7.2%) died of mel-
anoma—6 CSG patients and 7 ESG patients (p = 0.777).
A Cox proportional hazards model showed no significant
difference in DFS between the groups (HR 1.24
[0.42–3.71]; p = 0.69).
Cost Analysis
The total amount spent during the 3 years of follow-up
was €71,182.11 for the 43 CSG patients and €42,215.93 for
TABLE 3 Descriptives of patient-reported outcome measures at T1 and T3, and repeated measures ANOVAs (CSG, n = 56; ESG, n = 54)
Questionnaire Study group T1 mean (SD) T3 mean (SD) Repeated measures ANOVA
STAI-S Conventional 31.2 (8.3) 30.3 (9.4) F = 0.2; p = 0.66 (group)
Experimental 32.4 (8.1) 30.4 (7.9) F = 3.3; p = 0.07 (time)
F = 0.5; p = 0.48 (interaction)
CWS Conventional 4.6 (1.5) 4.0 (1.8) F = 0.3; p = 0.59 (group)
Experimental 5.1 (2.2) 3.8 (1.0) F = 22.5; p\ 0.001 (time), ES = 0.18
F = 3.3; p = 0.07 (interaction)
IES Conventional 23.3 (14.4) 14.0 (17.0) F = 11.4; p =0.001 (group), ES = 0.12
Experimental 14.0 (13.2) 6.2 (8.5) F = 31.5; p\ 0.001 (time), ES = 0.28
F = 0.23; p = 0.64 (interaction)
RAND-36 MCS score Conventional 49.6 (11.3) 53.5 (8.3) F = 0.004; p = 0.95 (group)
Experimental 48.6 (10.9) 54.3 (5.3) F = 21.2; p\ 0.001 (time), ES = 0.16
F = 0.81; p = 0.37 (interaction)
RAND-36 PCS score Conventional 48.9 (9.0) 52.4 (8.4) F = 5.4; p = 0.02 (group), ES = 0.05
Experimental 43.4 (11.3) 50.3 (10.6) F = 29.8; p\ 0.001 (time), ES = 0.22
F = 3.2; p = 0.08 (interaction)
CSG Conventional Study Group, ESG Experimental Study Group, T1 at inclusion, shortly after diagnosis, T3 3 years later, STAI-S State-Trait
Anxiety Inventory–State (range 20–80), CWS Cancer Worry Scale (range 3–12), IES Impact of Event Scale (range 15–75), MCS mental
component summary of the RAND-36 (standardized mean of 50, SD of 10), PCS physical component summary of the RAND-36 (standardized
mean of 50, SD of 10), F F-statistic, ES effect size, SD standard deviation, ANOVAs analyses of variance





schedule [n = 56]
Experimental
schedule [n = 54]
p value
Surgery 2450.00 2909.91
Total costs (€) 71,182.11 42,215.93
Costs per patient over 3 years [mean ± SD] (€) 1655.40 ± 921.3 1005.14 ± 745.05 0.001f
Data are expressed as n (%) unless otherwise specified
CSG Conventional Study Group, ESG Experimental Study Group, AJCC American Joint Committee on Cancer, GP general practitioner, NP
nurse practitioner, SD standard deviation, CT computed tomography
aHighest level of education completed (high: vocational education, university; intermediate: secondary vocational education, high school; low:
elementary school, low vocational education)
bSelf-designed questions
cChi square test
dIndependent student t test
eFisher’s exact test
fMann–Whitney U test
Significant p values are shown in bold
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the 42 ESG patients. The mean amount spent per ESG
patient was significantly lower than the amount spent per
CSG patient (p = 0.001) [Table 2], and the total cost
reduction was 39%. No significant differences were found
in total costs between the two hospitals.
DISCUSSION
The current study showed that 3 years after diagnosis,
patients assigned to the reduced stage-adjusted follow-up
schedule (ESG) reported levels of anxiety, cancer worry,
and mental health-related quality of life similar to those of
patients assigned to the follow-up schedule as currently
advised in the Dutch Melanoma guideline. Moreover, ESG
patients reported significantly lower levels of SRS. Addi-
tionally, over the 3-year period, recurrences and second
primary melanomas were detected within a comparable
time period in both groups, and the number of patients
dying from melanoma and time until death were equal.
Lastly, a reduced stage-adjusted follow-up schedule
resulted in a 39% cost reduction in the ESG. These results
support our hypotheses of no differences in PROMs,
recurrences and deaths between study groups, and lower
costs in the experimental group. They suggest that a less-
frequent follow-up schedule than is currently recom-
mended in the Dutch Melanoma guideline does not
negatively affect melanoma patients in terms of quality of
life, or in terms of the time until, and the number of
patients diagnosed with, recurrent disease and/or dying
from melanoma. Moreover, costs would be decreased.
The present 3-year results are in line with, and thus
support, the 1-year MELFO results.16 As at 1 year, at
3 years ESG patients reported suffering less from SRS. The
literature suggests that 50% of patients report having high
anxiety before and during outpatient clinic visits.26 Our
findings suggest that a less-frequent follow-up schedule,
thus less exposure to such anxious events, is beneficial in
the short- and long-term because it induces fewer SRS.
However, the ES of the between-group difference in SRS at
3 years is small, indicating that the difference is clinically
not relevant, while the ES at 1 year was moderately large.
This suggests that the difference in SRS between groups
becomes clinically irrelevant over time.
As after 1 year,16 after 3 years most ESG and CSG
patients were satisfied with the assigned schedule. This
implies that patients were content with the follow-up
schedule suggested by their doctor, be it conventional or
reduced. However, four-fifths of patients paid fewer or
more melanoma-related visits, indicating that patients seek
or decline medical attention when they judge it to be
necessary or not.




schedule [n = 93]
Experimental
schedule [n = 87]
p value
Total recurrence or second primary during 3-year follow-up 25 (13.9) 15 (16.1) 10 (11.5) 0.397a
Median time, days (range) 406 (179–1040) 369 (203–1040) 423 (179–984) 0.618b
Specifically 0.457c
Locoregional recurrence 11 (45.8) 8 (53.3) 3 (33.3)
Distant recurrence 6 (25) 3 (20) 3 (33.3)
Locoregional ? distant recurrence 2 (8.8) 2 (13.3)
Second primary 5 (20.8) 2 (13.3) 3 (33.3)
Missing 1 1
Detection of recurrence or second primary 0.204c
Patient 16 (66.7) 11 (78.6) 5 (50)
Specialist/NP 8 (33.3) 3 (21.4) 5 (50)
Missing 1 1
Died of melanoma during 3-years follow-up 13 (7.2) 6 (6.5) 7 (8) 0.777a
Median time, days (range) 780 (406–1169) 997 (415–1169) 712 (406–1017) 0.317b
Died of other cause 3 (1.7) 2 (2.2) 1 (1.1)
Data are expressed as n (%) unless otherwise specified
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A significantly higher percentage of ESG patients than
CSG patients paid extra visits to the medical specialist than
scheduled. However, of those who paid extra visits, two-
thirds of the ESG patients and more than half of the CSG
patients paid only one extra visit during the 3-year study
period. Therefore, it seems unlikely that extra visits will
have affected the 3-year results of the current study in
terms of experienced quality of life or detection of a
recurrence or second primary. Additionally, three-quarters
of patients paid extra visits to the GP, with, again, almost
half (in both groups) paying only one extra visit in the
3 years of follow-up. The reason for these extra visits may
be increased awareness of suspicious lesions, possibly
resulting from effective education on self-
inspection.4,11–14,26–29
The current 3-year results show that the number of
recurrences and second primary melanomas, and the time
until detection for patients with pathological sentinel node
staged AJCC stage IB–IIC, was independent of the
assigned follow-up schedule, which is in line with the
1-year MELFO results.16 Almost two-thirds of the recur-
rences were detected within the first year after diagnosis,
and two-fifths were detected between 1 and 3 years after
diagnosis. This is conform literature, showing that the
highest proportion of melanoma recurrences and second
primaries is detected during the first year of follow-up, and
that the proportion declines over the following
years.4,9,13,14
The present study showed that almost two-thirds of
patients detected a recurrence themselves, which, again, is
conform literature.13,14,26 No differences were found
between study groups, which suggests that the patient
information provided was comparable between study
groups.
Overall, the 3-year recurrence rate in the present study
was 13.9%, which is comparable with recent literature
reporting a rate of 14.7%.4 However, it is slightly lower
than the 19% reported in a retrospective study including
AJCC stage IA–IIC melanoma patients and with a much
longer follow-up period (range 0–26.6 years).9 An expla-
nation for the higher percentage found in that study may be
the inclusion of patients who had not been sentinel node
staged, resulting in underestimation of the disease stage
and, consequently, the risk of recurrence.30 Second,
although most recurrences are detected within 3 years after
diagnosis, some patients do develop a recurrence after
3 years.9
Thirteen patients in the current study died of their
melanoma within 3 years after diagnosis (7.2%), with no
difference between the follow-up schedule groups. This is
slightly lower than the 8.2% reported in another prospec-
tive study; however, that study followed patients until
4 years after diagnosis.4
There is no consensus in the literature with respect to
performing routine additional laboratory testing (biomark-
ers LDH, S-100B) and imaging (ultrasonography, chest
x-ray, positron emission tomography [PET], magnetic
resonance imaging [MRI]) during follow-up in pathologi-
cal sentinel node staged AJCC IB–II melanoma patients,
even in high-risk melanoma patients (stage IIB/C), with
some being in favor and others not.31 The argument of
those who are against is that three-quarters of first recur-
rences are detected by patients themselves. They
recommend to perform additional testing and imaging only
when (distant) recurrent disease is suspected.7,13,14,32 For
patients with local, regional, or metastatic disease, various
treatment options are available, namely systemic treatment
options such as BRAF/MEK inhibitors, and immunologic
strategies with CTLA4, PD-1/PD-L1 antagonists that result
in significantly improved survival rates33
After 3 years, a less-frequent follow-up schedule resul-
ted in a considerable cost reduction (39%), as found after
1 year.16 Healthcare costs are high, financially burdening
healthcare systems and societies. The present study shows
that a reduced stage-adjusted follow-up schedule is cost
effective and is safe for patients. Additionally, less-fre-
quent follow-up will save healthcare providers’ time, now
and in the future, considering the increasing melanoma
prevalence. Increasingly, in The Netherlands, melanoma-
trained nurse practitioners provide follow-up and specific
patient melanoma (E-health) education in dedicated mela-
noma clinics.29 This will further reduce costs in melanoma
care.
The current study has some limitations. First, 23% of
patients declined to participate at 3 years after diagnosis;
however, this percentage is lower than the dropout rate in
another prospective study in melanoma patients.4 Fortu-
nately, no differences were found in baseline
characteristics and PROMs between patients who did and
did not complete T3 questionnaires. Second, power anal-
ysis showed that 89 patients per group were needed. We
commenced with 93 patients in the CGS group and 87
patients in the ESG group. Due to the dropout rate over
3 years, the number of patients analyzed at T3 is lower
than envisaged. However, no differences in sociodemo-
graphic and illness-related variables were found between
participants in the two study groups at either T116 or T3.
Third, due to the small sample size, some analyses per-
formed should be interpreted carefully.
CONCLUSION
The 3-year results of the MELFO study seem to support
the notion that a reduced stage-adjusted follow-up schedule
is an appropriate, safe, and cost-effective alternative for
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pathological, sentinel node staged, AJCC stage IB–IIC
melanoma patients, in terms of quality of life, recurrences,
deaths, and financial costs, to the follow-up regimen as
advised in the current melanoma guideline.
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